文献速递核素与放射性配体治疗

177Lu-FAP-2286治疗晚期肺癌的疗效与安全性评价

Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer.
PubMed 文献 · Clin Nucl Med · 2024-05-26

单中心前瞻性研究纳入9例晚期肺癌患者,评估177Lu-FAP-2286肽靶向放射核素治疗的疗效与安全性。按RECIST 1.1和PERCIST 1.0标准评估短期疗效,部分代谢缓解占44%,总缓解率可达77.78%;中位总生存期10个月,中位无进展生存期6个月;随访期间未观察到III/IV级毒性事件。

要点

  • 9例晚期肺癌患者接受177Lu-FAP-2286治疗,部分代谢缓解44%,总缓解率77.78%。
  • 中位总生存期10个月,中位无进展生存期6个月。
  • 随访期间未观察到III/IV级毒性事件,治疗后纤维蛋白原显著下降。

核心结论

  • 177Lu-FAP-2286有潜力成为晚期肺癌患者可行的肽靶向放射核素治疗选择。

研究设计与样本

  • 单中心前瞻性研究,纳入9例符合纳入标准的晚期肺癌患者,接受177Lu-FAP-2286肽靶向放射核素治疗。

主要发现

  • 基于RECIST 1.1和PERCIST 1.0标准的结果具有可比性,44%的患者显示部分代谢缓解,33.3%为代谢稳定疾病,22.22%为代谢进展疾病。
  • 治疗后最高代谢缓解达66.89%,总缓解率可达77.78%。
  • 长期疗效评估中,中位总生存期为10个月,中位无进展生存期为6个月。
  • 无进展生存期最短(3个月)的2例患者开始肽靶向放射核素治疗相对较晚。
  • EORTC QLQ-C30 v3.0、东部肿瘤协作组和卡氏体能状态评分显示,177Lu-FAP-2286治疗后患者整体健康状况、症状反应和生活质量改善,临床症状最明显的改善为呼吸困难和癌性疼痛。

关键数值与推荐

  • 短期疗效采用RECIST 1.1和PERCIST 1.0标准评估,毒性反应采用CTCAE v5.0评估。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to evaluate the efficacy and safety of peptide-targeted radionuclide therapy (PTRT) with 177Lu-FAP-2286 in advanced lung cancer. PATIENTS AND METHODS: This single-center prospective study included 9 patients diagnosed with advanced lung cancer. These patients met the inclusion criteria and received PTRT with 177Lu-FAP-2286. Short-term efficacy was assessed using RECIST 1.1 and PERCIST 1.0 criteria. Long-term efficacy was evaluated through overall survival, progression-free survival (PFS), overall response rate, EORTC QLQ-C30 v3.0, Eastern Cooperative Oncology Group, and Karnofsky Performance Status. Toxicity response was assessed using CTCAE v5.0. RESULTS: The results based on RECIST 1.1 and PERCIST 1.0 criteria were comparable, with 44% of patients showing a partial metabolic response, 33.3% with stable metabolic disease, and 22.22% with progressive metabolic disease. The highest metabolic response after treatment reached 66.89%, and the overall response rate could reach 77.78%. In the long-term efficacy assessment, the median overall survival and PFS were 10 months and 6 months, respectively. The 2 patients with the lowest PFS (3 months) started PTRT relatively late. EORTC QLQ-C30 v3.0, Eastern Cooperative Oncology Group, and Karnofsky Performance Status scores showed that the overall health status, symptom response, and quality of life of patients improved after 177Lu-FAP-2286 treatment. The most noticeable improvements in clinical symptoms were dyspnea and cancer-related pain. No grade III/IV toxicity events were observed during follow-up period, and fibrinogen decreased significantly after treatment. CONCLUSIONS: 177Lu-FAP-2286 has the potential to be a viable PTRT option for patients with advanced lung cancer.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Xie Y, Ma J, Tang W, et al. Efficacy and Safety Evaluation of 177Lu-FAP-2286 in the Treatment of Advanced Lung Cancer. Clin Nucl Med. 2024. PMID: 39102810. doi:10.1097/RLU.0000000000005297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。